News | May 25, 2026
SMS Pharma posts 48% profit surge in FY26 as margins expand & portfolio shift drives growth
Revenue from operations climbed 13% to Rs. 886.87 crore
Revenue from operations climbed 13% to Rs. 886.87 crore
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Transition to a fermentation-based globally integrated CDMO platform
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Dr. Upadhyay brings over 25 years of global leadership experience across life sciences, regulated manufacturing, diagnostics, and research-led environments
Company’s EBITDA grew 29.3 per cent to Rs. 290.4 crore, while PAT rose 36.4 per cent to Rs. 137.7 crore
This collaboration across the NIPER network- Raebareli, Hajipur, Ahmedabad and Hyderabad is strengthening translational research and opnMe access
BMS is moving beyond conversational AI into what it describes as “agentic” systems
The company’s revenue stood at Rs. 287.68 crore, reflecting a 4.7 percent increase over Rs. 274.71 crore reported in FY25
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
Subscribe To Our Newsletter & Stay Updated
